Expertise in
7
conditions

Dr. Michael D. Zurenko

Radiation Oncology
Prisma Health-Upstate
65 International Dr, 
Greenville, SC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
7
conditions
Prisma Health-Upstate
65 International Dr, 
Greenville, SC 

Overview

Michael Zurenko is a Radiation Oncologist practicing medicine in Greenville, South Carolina.

Dr. Zurenko is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Intraductal Papilloma, Angiosarcoma, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, participating in 16 clinical trials. Dr. Zurenko is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Prisma Health-Upstate
65 International Dr, Greenville, SC 29615

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
View 8 Less Clinical Trials
Similar Doctors
Expertise in
19
conditions
Dr. Michael P. Greenbaum
Radiation Oncology
Expertise in
19
conditions
Dr. Michael P. Greenbaum
Radiation Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute – Faris Rd.

900 West Faris Road, 
Greenville, SC 
 (5.6 miles away)
864-679-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Greenbaum is a Radiation Oncologist practicing medicine in Greenville, South Carolina. Dr. Greenbaum is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Posterior Fossa Tumor. Dr. Greenbaum is board certified in American Board Of Radiology. Dr. Greenbaum is currently accepting new patients.

Expertise in
51
conditions
Dr. Heather N. Allen
Radiation Oncology
Expertise in
51
conditions
Dr. Heather N. Allen
Radiation Oncology
Referral may be required

Medical Group Of The Carolinas-Radiation Oncology-Spartanburg

380 Serpentine Dr, 
Spartanburg, SC 
 (23.2 miles away)
864-560-6917
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Heather Allen is a Radiation Oncologist practicing medicine in Spartanburg, South Carolina. Dr. Allen is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Teratocarcinosarcoma, Olfactory Neuroblastoma, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Allen is currently accepting new patients.

Expertise in
23
conditions
Dr. Drew C. Monitto
Radiation Oncology
Expertise in
23
conditions
Dr. Drew C. Monitto
Radiation Oncology
Referral may be required

Medical Group Of The Carolinas-Radiation Oncology-Spartanburg

380 Serpentine Dr, 
Spartanburg, SC 
 (23.2 miles away)
864-560-6917
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Drew Monitto is a Radiation Oncologist practicing medicine in Spartanburg, South Carolina. Dr. Monitto is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Posterior Fossa Tumor, and Lung Cancer. Dr. Monitto is currently accepting new patients.

Frequently Asked Questions about Dr. Michael D. Zurenko

How do I make an appointment with Dr. Michael D. Zurenko?

You can book an appointment with Dr. Michael D. Zurenko by calling their office at 864-987-7000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael D. Zurenko a top-rated expert for Familial Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael D. Zurenko is classified as an Distinguished expert for Familial Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael D. Zurenko specialize in?

While Dr. Michael D. Zurenko is a Radiation Oncology, they have specific expertise in Familial Prostate Cancer, Intraductal Papilloma, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Michael D. Zurenko accept my insurance?

Dr. Michael D. Zurenko accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-987-7000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zurenko's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile